Stock Events

Stock Events

Cardiff Oncology 

$1.71
0
+$0.11+6.87% Wednesday 07:54

Statistics

Day High
1.71
Day Low
1.71
52W High
-
52W Low
-
Volume
2
Avg. Volume
-
Mkt Cap
115.19M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2025
Q4 2025
Next
-0.21
-0.17
-0.14
-0.11
Expected EPS
-0.134625
Actual EPS
N/A

Financials

-6,655.2%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.37MRevenue
-90.91MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 10.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRDF.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad oncology portfolio, including targeted therapies and immunotherapies that compete across multiple areas of cancer treatment.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol Myers Squibb offers a wide range of cancer treatments, including targeted therapies and immunotherapies, directly competing with Cardiff Oncology's approach to cancer treatment.
Merck
MRK
Mkt Cap214.76B
Merck is known for its strong oncology pipeline, including blockbuster cancer drug Keytruda, competing in the space of innovative cancer therapies.
AMGEN
AMGN
Mkt Cap160.66B
Amgen has a diverse oncology portfolio, including treatments for solid tumors and hematologic malignancies, making it a competitor in the broader oncology market.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, with its acquisition of Kite Pharma, has become a leader in cell therapy for cancer, competing in the innovative treatment space alongside Cardiff Oncology.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad oncology portfolio, including targeted therapies and immunotherapies, competing in various cancer treatment areas.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, with its acquisition of Pharmacyclics, has strengthened its oncology portfolio, competing in the space of cancer treatment with a focus on hematologic malignancies.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, known for its innovative biologics, competes in the oncology space with treatments that could potentially overlap with Cardiff Oncology's target patient populations.

About

Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company's TROV-053 is also in Phase II clinical trial in combination with Zytiga for metastatic castration-resistant prostate cancer. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Show more...
CEO
ISIN
US14147L1089

Listings

XNAS
US
CRDF
F
DE
XE7C.F
BOATS
BOATS
CRDF.BOATS

0 Comments

Share your thoughts

FAQ

What is Cardiff Oncology stock price today?▼
The current price of CRDF.BOATS is $1.71 USD — it has increased by +6.87% in the past 24 hours. Watch Cardiff Oncology stock price performance more closely on the chart.
What is Cardiff Oncology stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cardiff Oncology stocks are traded under the ticker CRDF.BOATS.
What is Cardiff Oncology market cap?▼
Today Cardiff Oncology has the market capitalization of 115.19M
When is the next Cardiff Oncology earnings date?▼
Cardiff Oncology is going to release the next earnings report on April 30, 2026.
What were Cardiff Oncology earnings last quarter?▼
CRDF.BOATS earnings for the last quarter are -0.11 USD per share, whereas the estimation was -0.19 USD resulting in a +41.8% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cardiff Oncology revenue for the last year?▼
Cardiff Oncology revenue for the last year amounts to 1.37M USD.
What is Cardiff Oncology net income for the last year?▼
CRDF.BOATS net income for the last year is -90.91M USD.
When did Cardiff Oncology complete a stock split?▼
Cardiff Oncology has not had any recent stock splits.